Avalo Reports First Quarter 2024 Financial Results and Provides Business Updates

Topline results from planned Phase 2 trial of AVTX-009 in hidradenitis suppurativa expected in 2026Cash on hand of approximately $110 million as of March 31, 2024 with expected cash runway into 2027 WAYNE, Pa. and ROCKVILLE, Md., May 13, 2024 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX), today announced business updates and financial results for the first quarter of 2024. "Over the past month we have made considerable progress toward initiating our planned Phase 2 trial of AVTX-009 in hidraden ...